Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
Arvinas, Inc. announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulves...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced new findings from the SLIM LIVER study (also known as A5371)...
CervoMed Inc. a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), announced positive ...
Kodiak Sciences Inc. announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic r...
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
Celltrion announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimila...
Bristol Myers Squibb announced positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of ...
Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...
Johnson & Johnson announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-t...
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, and Tiefenbacher Group, a leading healthcare company...
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced the first patient has been dosed in the co...
Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...
© 2025 Biopharma Boardroom. All Rights Reserved.
